Antares Pharma (ATRS) is being set up to run to at least $3.85, Thesis follows below; The chart above shows “quiet” accumulation. The purple line is the accumulation, notice for the first time, the accumulation points up, MACDÂ and RSI…
Tag: biotechs
Why the latest rally could be a bull trap
This week has been a strange market week for sure. I have held back on picks mainly because I want to see some clarity as I believe we are at a market top, and economic data has peaked out. Furthermore,…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
DARA Poised to Break Out on Catalysts
DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
Tuesday’s Small Cap Biopharma Catalyst Trade List
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
